dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
Published 6 years ago • 305 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
0:57
dr. mirza on impact of niraparib in ovarian cancer
-
1:30
dr. mirza on niraparib efficacy across ovarian cancer subgroups
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
1:14
dr. arend on niraparib with bevacizumab in ovarian cancer
-
2:18
dr. mirza on final data of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
1:42
final ananova2 survival data support niraparib plus bevacizumab in recurrent ovarian cancer
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
2:11
dr. mirza on the rationale for the avanova trial in recurrent ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
3:11
the avanova study: niraparib and bevacizumab for ovarian cancer
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
2:25
results of niraparib/bevacizumab combo in platinum-sensitive recurrent ovarian cancer
-
2:20
dr. matulonis discusses niraparib/pembrolizumab combo in platinum-resistant ovarian cancer
-
0:56
dr. mirza on the implications of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
8:29
esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer
-
3:14
personalized dosing of niraparib in ovarian cancer